Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for new non-executive employees on November 1, 2022. A total of 7,250 shares will vest over a three-year period, with one-third vesting on the first anniversary of the commencement date and subsequent one-sixth vesting every six months. These awards are part of the 2017 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4). Puma focuses on developing innovative cancer treatments, including its approved drug NERLYNX®.

Puma Biotechnology (NASDAQ: PBYI) presented updated results from the Phase II SUMMIT trial on neratinib for EGFR exon 18-mutant NSCLC at the EORTC/NCI/AACR Symposium in Barcelona on October 27. The trial included 29 patients, showing an overall objective response rate (ORR) of 35%, with 50% in TKI-naïve patients. Adverse events were primarily diarrhea, with no grade 4 incidents reported. The interim findings indicate neratinib may be a promising option for patients with limited treatment options. Final data will be released later.

Puma Biotechnology (NASDAQ: PBYI) will host a conference call on November 3, 2022, at 1:30 p.m. PDT to discuss its third quarter financial results. Interested parties can access the call via telephone or through a live webcast on the company’s website. Puma's NERLYNX (neratinib) has been approved for treating early-stage HER2-overexpressed breast cancer and advanced HER2-positive breast cancer. In September 2022, Puma secured an exclusive license for alisertib, aiming to develop it for small cell lung cancer and breast cancer.

Puma Biotechnology (NASDAQ: PBYI) announced on October 3, 2022, the approval of inducement restricted stock unit awards covering 26,875 shares to five new non-executive employees. These awards, granted under the 2017 Employment Inducement Incentive Award Plan, vest over three years, with one-third vesting on the first anniversary and the remainder on subsequent six-month anniversaries. The awards are intended to facilitate the hiring of new staff, in compliance with Nasdaq rules.

Puma Biotechnology (NASDAQ: PBYI) has secured a licensing agreement with Takeda for worldwide rights to alisertib, a small-molecule inhibitor targeting aurora kinase A. This agreement includes a $7 million upfront fee and potential milestone payments up to $287.3 million, alongside tiered royalties on sales. Puma aims to develop alisertib for metastatic ER-positive HER2-negative breast cancer, triple-negative breast cancer, and small cell lung cancer, with previous trials showing promising clinical activity.

Puma Biotechnology (NASDAQ: PBYI) presented updated findings from the Phase II SUMMIT trial of neratinib for HER2-mutant, metastatic cervical cancer at the 2022 ESMO Congress in Paris. The trial involved 22 patients, showing an objective response rate of 18.2% and a clinical benefit rate of 45.5%. Median progression-free survival was 5.1 months. Diarrhea was the most common adverse event (81.8%), manageable with prophylaxis. Dr. Friedman highlighted neratinib's potential as a treatment option for HER2-mutant cervical cancer, while CEO Alan Auerbach expressed satisfaction with the positive outcomes.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that CEO Alan H. Auerbach will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The virtual presentation starts at 7:00 a.m. EDT on September 12, 2022 and will be available for 30 days on Puma's website. Puma specializes in developing innovative cancer treatments, notably NERLYNX® (neratinib), approved by the FDA for specific breast cancer treatments. More information can be found at Puma's website.

Puma Biotechnology (NASDAQ: PBYI) announced on September 1, 2022, that its Compensation Committee approved inducement restricted stock unit awards for 18,750 shares to two new non-executive employees. These awards are under the 2017 Employment Inducement Incentive Award Plan and will vest over three years, with one-third vesting on the first anniversary and one-sixth every six months thereafter. The awards were granted to incentivize new employees as per Nasdaq Listing Rule 5635(c)(4).

Toragen, Inc., a biotechnology firm focused on treating HPV-induced cancers, has announced new board appointments. Mr. Paul Engler, a seasoned investor, joins the Board of Directors, while Cheryl Collett has been appointed CFO effective June 20, 2022. Collett, with over 20 years in finance, previously worked at Puma Biotechnology (NASDAQ: PBYI). Dr. Richard Lumpkin will lead Research & Development starting July 1, 2022. Engler commended Toragen’s team and unique platform, highlighting the company's commitment to addressing HPV-related health issues.